Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FC vs FCR in Untreated Mantle Cell Lymphoma
NCT00053092Phase 2Completed
- Sponsor
- The Institute of Cancer Research
- Start
- Oct 2002
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of rituximab in mantle cell lymphoma (MCL) (2 arms), sponsored by The Institute of Cancer Research. Primary endpoints: Response Rate, Time to Disease Progression and 2 more. Started Oct 2002; status: completed.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00053092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00053092.